Long-term outcome of stereotactic brachytherapy with temporary Iodine-125 seeds in patients with WHO grade II gliomas.
Grade II glioma
Iodine-125 seeds
Low-grade glioma
Stereotactic brachytherapy
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
09 Dec 2020
09 Dec 2020
Historique:
received:
02
09
2020
accepted:
13
11
2020
entrez:
10
12
2020
pubmed:
11
12
2020
medline:
19
8
2021
Statut:
epublish
Résumé
This long-term retrospective analysis aimed to investigate the outcome and toxicity profile of stereotactic brachytherapy (SBT) in selected low-grade gliomas WHO grade II (LGGII) in a large patient series. This analysis comprised 106 consecutive patients who received SBT with temporary Iodine-125 seeds for histologically verified LGGII at the University of Munich between March 1997 and July 2011. Investigation included clinical characteristics, technical aspects of SBT, the application of other treatments, outcome analyses including malignization rates, and prognostic factors with special focus on molecular biomarkers. For the entire study population, the 5- and 10-years overall survival (OS) rates were 79% and 62%, respectively, with a median follow-up of 115.9 months. No prognostic factors could be identified. Interstitial radiotherapy was applied in 51 cases as first-line treatment with a median number of two seeds (range 1-5), and a median total implanted activity of 21.8 mCi (range 4.2-43.4). The reference dose average was 54.0 Gy. Five- and ten-years OS and progression-free survival rates after SBT were 72% and 43%, and 40% and 23%, respectively, with a median follow-up of 86.7 months. The procedure-related mortality rate was zero, although an overall complication rate of 16% was registered. Patients with complications had a significantly larger tumor volume (p = 0.029). SBT is a minimally invasive treatment modality with a favorable outcome and toxicity profile. It is both an alternative primary treatment method as well as an adjunct to open tumor resection in selected low-grade gliomas.
Sections du résumé
BACKGROUND
BACKGROUND
This long-term retrospective analysis aimed to investigate the outcome and toxicity profile of stereotactic brachytherapy (SBT) in selected low-grade gliomas WHO grade II (LGGII) in a large patient series.
METHODS
METHODS
This analysis comprised 106 consecutive patients who received SBT with temporary Iodine-125 seeds for histologically verified LGGII at the University of Munich between March 1997 and July 2011. Investigation included clinical characteristics, technical aspects of SBT, the application of other treatments, outcome analyses including malignization rates, and prognostic factors with special focus on molecular biomarkers.
RESULTS
RESULTS
For the entire study population, the 5- and 10-years overall survival (OS) rates were 79% and 62%, respectively, with a median follow-up of 115.9 months. No prognostic factors could be identified. Interstitial radiotherapy was applied in 51 cases as first-line treatment with a median number of two seeds (range 1-5), and a median total implanted activity of 21.8 mCi (range 4.2-43.4). The reference dose average was 54.0 Gy. Five- and ten-years OS and progression-free survival rates after SBT were 72% and 43%, and 40% and 23%, respectively, with a median follow-up of 86.7 months. The procedure-related mortality rate was zero, although an overall complication rate of 16% was registered. Patients with complications had a significantly larger tumor volume (p = 0.029).
CONCLUSION
CONCLUSIONS
SBT is a minimally invasive treatment modality with a favorable outcome and toxicity profile. It is both an alternative primary treatment method as well as an adjunct to open tumor resection in selected low-grade gliomas.
Identifiants
pubmed: 33298103
doi: 10.1186/s13014-020-01719-9
pii: 10.1186/s13014-020-01719-9
pmc: PMC7724805
doi:
Substances chimiques
Iodine Radioisotopes
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
275Références
J Neurooncol. 2004 Aug-Sep;69(1-3):83-100
pubmed: 15527082
Lancet Oncol. 2016 Nov;17(11):1521-1532
pubmed: 27686946
J Neurooncol. 2015 Dec;125(3):503-30
pubmed: 26530265
Cancer. 2006 Mar 15;106(6):1372-81
pubmed: 16470609
J Clin Oncol. 2008 Mar 10;26(8):1338-45
pubmed: 18323558
Strahlenther Onkol. 2016 Nov;192(11):759-769
pubmed: 27363701
J Neurooncol. 2015 Dec;125(3):609-30
pubmed: 26530264
J Neurooncol. 2015 Dec;125(3):551-83
pubmed: 26530266
J Neurooncol. 2015 Dec;125(3):585-607
pubmed: 26530261
Radiother Oncol. 1997 Jun;43(3):253-60
pubmed: 9215784
J Neurosurg. 2011 Mar;114(3):566-73
pubmed: 20635853
Radiat Oncol. 2012 Mar 06;7:30
pubmed: 22394548
Cancer. 2015 May 15;121(10):1712-9
pubmed: 25585890
Cancer. 1993 Jul 1;72(1):190-5
pubmed: 8508405
Neurosurgery. 1995 Feb;36(2):275-82; discussion 282-4
pubmed: 7731507
Acta Neurochir (Wien). 1992;119(1-4):53-61
pubmed: 1481753
Br J Cancer. 2003 Aug;89 Suppl 1:S73-83
pubmed: 12915906
N Engl J Med. 2016 Apr 7;374(14):1344-55
pubmed: 27050206
Cancer. 1997 Jan 15;79(2):370-9
pubmed: 9010111
Neurosurg Focus. 2015 Mar;38(3):E2
pubmed: 25727224
J Neurol. 2008 Oct;255(10):1495-502
pubmed: 18677635
Adv Tech Stand Neurosurg. 2010;35:183-212
pubmed: 20102115
Ann Oncol. 2012 Sep;23 Suppl 10:x28-32
pubmed: 22987977
Strahlenther Onkol. 2015 Dec;191(12):936-44
pubmed: 26307628
Semin Radiat Oncol. 2015 Jul;25(3):155-63
pubmed: 26050585
J Clin Oncol. 2002 Apr 15;20(8):2076-84
pubmed: 11956268
J Neurosurg. 1995 Mar;82(3):418-29
pubmed: 7861220
J Neurol. 2004 Dec;251(12):1455-64
pubmed: 15645344
J Neurooncol. 1993 Sep;17(3):253-60
pubmed: 8164061
Eur J Neurol. 2010 Sep;17(9):1124-33
pubmed: 20718851
Neuro Oncol. 2011 Oct;13(10):1133-42
pubmed: 21868412
Adv Anat Pathol. 2015 Mar;22(2):94-101
pubmed: 25664944
J Neurooncol. 2015 Dec;125(3):481-501
pubmed: 26530259
Strahlenther Onkol. 2016 Sep;192(9):672-4
pubmed: 27402390
Cancer. 1994 Sep 15;74(6):1784-91
pubmed: 8082081
J Neurooncol. 2015 Dec;125(3):531-49
pubmed: 26530263